Visioneering Technologies, Inc., a medical device company, engages in the design, manufacture, sale, and distribution of contact lenses in North America, Europe, and the Asia-Pacific.
Visioneering Technologies Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.99|
|52 Week High||AU$0.94|
|52 Week Low||AU$4.20|
|1 Month Change||5.85%|
|3 Month Change||-11.16%|
|1 Year Change||-75.73%|
|3 Year Change||-94.47%|
|5 Year Change||n/a|
|Change since IPO||-97.76%|
Recent News & Updates
Health Check: How Prudently Does Visioneering Technologies (ASX:VTI) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|VTI||AU Medical Equipment||AU Market|
Return vs Industry: VTI underperformed the Australian Medical Equipment industry which returned -6.5% over the past year.
Return vs Market: VTI underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: VTI is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: VTI's weekly volatility (7%) has been stable over the past year.
About the Company
Visioneering Technologies, Inc., a medical device company, engages in the design, manufacture, sale, and distribution of contact lenses in North America, Europe, and the Asia-Pacific. It offers NaturalVue, a multifocal contact lens for adults with presbyopia and children with myopia. The company was incorporated in 2008 and is headquartered in Alpharetta, Georgia.
Visioneering Technologies Fundamentals Summary
|VTI fundamental statistics|
Is VTI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VTI income statement (TTM)|
|Cost of Revenue||US$5.18m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.23|
|Net Profit Margin||-89.79%|
How did VTI perform over the long term?See historical performance and comparison
Is Visioneering Technologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate VTI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate VTI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: VTI is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: VTI is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VTI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VTI is good value based on its PB Ratio (1.6x) compared to the AU Medical Equipment industry average (5x).
How is Visioneering Technologies forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VTI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VTI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VTI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VTI's revenue (37.6% per year) is forecast to grow faster than the Australian market (5.4% per year).
High Growth Revenue: VTI's revenue (37.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VTI is forecast to be unprofitable in 3 years.
How has Visioneering Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VTI is currently unprofitable.
Growing Profit Margin: VTI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VTI is unprofitable, but has reduced losses over the past 5 years at a rate of 12.7% per year.
Accelerating Growth: Unable to compare VTI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VTI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: VTI has a negative Return on Equity (-51.4%), as it is currently unprofitable.
How is Visioneering Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: VTI's short term assets ($17.7M) exceed its short term liabilities ($4.6M).
Long Term Liabilities: VTI's short term assets ($17.7M) exceed its long term liabilities ($2.9M).
Debt to Equity History and Analysis
Debt Level: VTI's debt to equity ratio (26.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if VTI's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VTI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VTI has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 0.2% each year.
What is Visioneering Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VTI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VTI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VTI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VTI's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Stephen Snowdy (51 yo)
Dr. Stephen Snowdy, Ph D., has been Chief Executive Officer of Visioneering Technologies, Inc. June 2013, its Executive Director since November 25, 2008 and served as its President. Dr. Snowdy is a scienti...
CEO Compensation Analysis
Compensation vs Market: Stephen's total compensation ($USD331.01K) is about average for companies of similar size in the Australian market ($USD302.06K).
Compensation vs Earnings: Stephen's compensation has been consistent with company performance over the past year.
Experienced Management: VTI's management team is considered experienced (4.1 years average tenure).
Experienced Board: VTI's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 142.6%.
Visioneering Technologies, Inc.'s employee growth, exchange listings and data sources
- Name: Visioneering Technologies, Inc.
- Ticker: VTI
- Exchange: ASX
- Founded: 2008
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: AU$23.517m
- Shares outstanding: 23.64m
- Website: https://vtivision.com
Number of Employees
- Visioneering Technologies, Inc.
- 10745 Westside Way
- Suite 200
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 15:29|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.